RMD Form 4: CEO sold 8,009 shares at $278.14 and acquired 8,009 at $101.64

Rhea-AI Filing Summary

Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), reported transactions on Form 4 relating to common stock and stock options. On 09/08/2025 he acquired 8,009 shares at $101.64 per share under a Rule 10b5-1 plan adopted October 31, 2024, and sold 8,009 shares in multiple trades at a weighted-average price of $278.1359 (trade prices ranged $275.27–$279.57). Following the reported transactions his direct beneficial ownership is reported as 475,801 shares after the purchase and 467,792 shares after the sale, with an additional 2,090 shares held indirectly via the Lisette and Michael Farrell Family Trust. He also reports holding 16,020 options exercisable through 11/14/2025; options vest one-third per year.

Positive

• Transactions executed under a Rule 10b5-1 plan, providing pre-arranged, documented trading intent (plan adopted October 31, 2024).
• Timely disclosure with Form 4 signed by the reporting person on 09/09/2025.
• Detailed holdings disclosed: direct beneficial ownership figures and indirect trust holdings are reported, plus option counts and vesting information.

Negative

• Insider sale of 8,009 shares at a weighted-average price of $278.1359, which could be interpreted as a material disposition by an officer.
• Net decrease in reported direct holdings from 475,801 to 467,792 following the reported sale.

Insights

Financial Analyst

TL;DR: Insider sold 8,009 shares at a high weighted-average price and concurrently acquired 8,009 shares under a 10b5-1 plan; net holdings remain substantial.

The Form 4 shows concurrent sale and purchase activity executed under a Rule 10b5-1 plan, indicating pre-arranged transactions rather than ad hoc trading. The sale executed at a weighted-average of $278.1359 and the purchase at $101.64 are distinct economic events: the purchase price reflects option exercise or plan terms while the sale proceeds reflect market exits. Reported direct beneficial ownership remains in the high hundreds of thousands of shares and total option holdings (16,020) extend through November 2025. For investors, this is a disclosure of insider activity rather than new operational or financial information about the company.

Corporate Governance Expert

TL;DR: Transactions were conducted under a documented 10b5-1 plan and are disclosed promptly, aligning with standard governance practices.

The filing indicates the 10b5-1 plan was adopted October 31, 2024, and the Form 4 is signed and dated 09/09/2025, showing timely reporting. The file details indirect holdings via a family trust and clearly lists option exercisability and vesting (one-third per year), which aids transparency. There are no governance red flags in the filing text itself; it communicates beneficial ownership and option schedules as required by Section 16 reporting rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	09/08/2025		M(1)		8,009	A	$101.64	475,801	D
ResMed Common Stock	09/08/2025		S(1)		8,009	D	$278.1359(2)	467,792	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	09/08/2025		M			8,009	11/11/2019(3)	11/14/2025	ResMed Common Stock	8,009	$0	16,020	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $275.27 - $279.57. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	Michael J. Farrell, Chief Executive Officer	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ResMed CEO Michael J. Farrell report on Form 4 (RMD)?

He reported acquiring 8,009 shares at $101.64 and selling 8,009 shares at a weighted-average price of $278.1359 on 09/08/2025.

Were these trades part of a 10b5-1 plan for Michael J. Farrell (RMD)?

Yes. The filing states the transactions were conducted under a Rule 10b5-1 plan adopted on October 31, 2024.

How many ResMed shares does Michael J. Farrell beneficially own after the transactions?

The Form 4 reports direct beneficial ownership of 467,792 shares after the sale and notes 2,090 shares held indirectly via a family trust.

What derivative holdings did the Form 4 disclose for Michael J. Farrell?

He reports holding 16,020 options with an exercise price of $101.64, exercisable beginning 11/11/2019 and expiring 11/14/2025; options vest one-third per year.

When was the Form 4 signed and filed by the reporting person?

The Form 4 is signed by Michael J. Farrell on 09/09/2025.